Merna Therapeutics
PrivateLast Round
M&A
Aug 28, 2017
Est. Valuation
$145.81M
Total Funding Raised
$102.87M
Company Overview
Merna Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series D round in April 2015.
Merna Therapeutics is a biotechnology company focused on the development of RNA-based therapies and polypeptide-based treatments for oncology and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Merna Therapeutics Comparables
Compare Merna Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shape Therapeutics | 79% | |
| EdiGene | 77% | |
| ProQR Therapeutics | 76% |
For institutional investors. Book with your work email.
Merna Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Aug 28, 2017 | ||||
| IPO | Oct 1, 2015 | ||||
| Series D | Apr 30, 2015 | ||||
| Grant | May 21, 2014 | ||||
| Series C | Oct 24, 2012 | ||||
Series B | Aug 23, 2011 |
For institutional investors. Book with your work email.
Merna Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Enterprise Associates | Series C, Series D |
| Baxter Ventures | Series D |
| Morningside Ventures | Series D |
| Osage University Partners | Series C, Series D |
| Santé Ventures | Series D |
| National Institutes of Health (NIH) | Grant |
| Rock Springs Capital | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 28, 2017
Raised M&A round with Synlogic, Inc.
- Oct 1, 2015
$44M raised in IPO round.
For institutional investors. Book with your work email.
Merna Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Merna Therapeutics's valuation, stock price, and market status.
Is Merna Therapeutics a public or private company?
Merna Therapeutics is a private company.
What is the current stock price of Merna Therapeutics?
Merna Therapeutics is a private company, so its shares have no public market price. Caplight tracks Merna Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Merna Therapeutics worth (valuation)?
Merna Therapeutics's valuation is estimated at $145.8M based on funding round data.
Can I buy Merna Therapeutics stock?
Merna Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Merna Therapeutics's last funding round?
Merna Therapeutics's most recent funding round was M&A on August 28, 2017.
Who are the main investors in Merna Therapeutics?
Key investors in Merna Therapeutics include Baxter Ventures, Sofinnova Investments.
Will Merna Therapeutics IPO soon?
No public IPO plans have been announced for Merna Therapeutics.
How can I track Merna Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Merna Therapeutics's shares on secondary markets.